10-Q: 23andMe Winds Down Operations After Asset Sale

23andMe Holding Co. reports significant revenue decline and ongoing losses, confirming a wind-down of operations following the sale of most assets to a related party.

Summary

• 23andMe Holding Co. and its subsidiaries filed for Chapter 11 bankruptcy on March 23, 2025.
• On July 14, 2025, the company completed the sale of substantially all its assets, including the Personal Genome Service (PGS) and research services, to 23andMe Research Institute (an affiliate of co-founder Anne Wojcicki) for $305.0 million in cash.
• The company received $302.5 million in cash from the asset sale, excluding $2.5 million related to the telehealth business.
• The company plans to sell its remaining telehealth business, Lemonaid Health, and then wind down all other operations, expecting to cease existence after asset distribution.
• Net loss from continuing operations for the three months ended June 30, 2025, was $23.8 million, a significant improvement from $54.9 million in the prior year period.
• Total revenue decreased by 37% to $25.4 million for the three months ended June 30, 2025, compared to $40.4 million in the same period last year.
• Service revenue decreased by $14.1 million, primarily due to a $15.2 million drop in PGS kit revenue from lower sales volume and average selling price.
• Product revenue decreased by $0.9 million, mainly from lower telehealth medical visits and pharmacy sales.
• Gross profit decreased by 34% to $13.5 million, but gross margin improved from 51% to 53%.
• Operating expenses decreased by 43% to $44.2 million, driven by reductions in force, lower advertising spend, and reduced facilities expenses.
• The company incurred $6.8 million in net reorganization items for the quarter, including $35.8 million in professional fees and $0.5 million in DIP financing fees, offset by $43.1 million in adjustments to lease liabilities.
• Outstanding borrowings under the Debtor-in-Possession (DIP) facility were $25.0 million as of June 30, 2025, which were repaid on July 14, 2025.
• The company was delisted from Nasdaq on March 31, 2025, and its Class A common stock began trading on the OTC Pink Market under the symbol MEHCQ.
• A $10.0 million break-up fee was paid to Regeneron Pharmaceuticals, Inc. on July 16, 2025, related to the asset sale.

Sentiment

Score: 1

Explanation: The company is in Chapter 11 bankruptcy, has sold substantially all its core assets, and plans to wind down its remaining operations and cease existence. This represents a complete failure of the business model and a catastrophic outcome for shareholders, despite the cash infusion from the asset sale.

Positives

• The company completed the sale of substantially all assets for $305.0 million, providing a significant cash infusion.
• Net loss from continuing operations decreased by 57% to $23.8 million, compared to $54.9 million in the prior year, indicating reduced operating expenses.
• Gross margin improved from 51% to 53% for the three months ended June 30, 2025, despite lower revenue.
• Operating expenses significantly decreased by 43% due to workforce reductions, lower advertising, and lease abandonments.

Negatives

• Total revenue decreased by 37% year-over-year, primarily due to lower PGS kit sales and telehealth revenue.
• The company filed for Chapter 11 bankruptcy, indicating severe financial distress.
• Delisting from Nasdaq and trading on the OTC Pink Market signifies a loss of major exchange listing and reduced liquidity.
• The company plans to sell its remaining business (Lemonaid Health) and wind down all other operations, leading to cessation of existence.
• Significant operating losses continue, with an accumulated deficit of $2.5 billion as of June 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern.

Risks

• Realization of assets and satisfaction of liabilities are subject to uncertainty during the Chapter 11 wind-down process.
• The company continues to incur material reorganization expenses related to the Chapter 11 Cases, which could increase over time.
• The ultimate settlement of liabilities subject to compromise is dependent on the outcome of the Chapter 11 Cases and may be materially adjusted.
• Any approved Chapter 11 plan could materially change the amounts of assets and liabilities reported.
• The company does not expect to engage in any revenue-generating activities other than the operations of Lemonaid Health, which is also planned for sale.
• Ongoing litigation and regulatory matters related to the October 2023 Cyber Incident, including class action and arbitration claims, have resulted in significant settlement costs ($37.5 million aggregate agreed settlement, $9.0 million additional recorded settlements/fines in the quarter).
• The company relies on single suppliers for microarrays and kits, and a single laboratory service provider, posing concentration risk.
• Competition in the telehealth market continues to intensify, potentially impacting Lemonaid Health's performance prior to its sale.

Future Outlook

The company plans to sell its remaining telehealth business, Lemonaid Health, and then wind down the remainder of its operations, expecting to cease existence following the distribution of all remaining assets. It does not expect to engage in any revenue-generating activities other than Lemonaid Health's operations.

Management Comments

• Management believes the sale to TTAM Research Institute is the highest or otherwise best bid for the Acquired Assets.
• The interim Chief Executive Officer and Chief Financial Officer, Joseph Selsavage, certified that the financial statements fairly present the company's financial condition and results of operations.

Industry Context

The company's exit from the direct-to-consumer genetic testing and research services, coupled with its plan to sell its telehealth business, reflects a significant contraction in its market presence. The telehealth market is noted as highly competitive with many participants, including new entrants and traditional healthcare systems, intensifying competition for Lemonaid Health.

Comparison to Industry Standards

• Direct comparison to industry standards is difficult given the company's Chapter 11 bankruptcy status and ongoing wind-down process. Its financial performance is no longer indicative of a typical operating business.
• The delisting from Nasdaq and move to OTC Pink Market places the company outside the standard benchmarks for publicly traded companies on major exchanges.
• The sale of core assets (PGS and research services) to a related party, TTAM Research Institute, for $305.0 million, is a unique event driven by the bankruptcy process rather than typical market M&A activity.
• The company's accumulated deficit of $2.5 billion and substantial doubt about its going concern status are severe indicators of underperformance relative to industry peers that are not in bankruptcy.

Management Changes

Corporate Governance

Legal Proceedings

• Multiple class action claims filed in federal and state courts in California and other jurisdictions, and arbitration claims asserted, related to the October 2023 Cyber Incident.
• Company reached an agreement in principle for a $30.0 million aggregate cash payment to settle U.S. class action lawsuits related to the Cyber Incident.
• Entered into settlements with arbitration claimants and state court plaintiffs for an aggregate of $37.5 million to settle claims related to the Cyber Incident.
• The United Kingdom's Information Commissioners Office fined the company for conduct relating to the Cyber Incident.
• As of June 30, 2025, $49.0 million of accrued expenses related to estimated loss contingencies and legal fees for the Cyber Incident are included in liabilities subject to compromise, offset by $18.0 million of insurance recoveries.

Related Party Transactions

• The company had an ongoing collaboration with GlaxoSmithKline (GSK), which held a 42.6% voting interest as of June 30, 2025. Research services revenue related to the 2023 GSK Amendment was $0.1 million for the three months ended June 30, 2025.
• The Anne Wojcicki Foundation, affiliated with co-founder Anne Wojcicki, subscribed for Class A common stock in connection with the merger.
• The Troper Wojcicki Foundation (TWF), affiliated with Anne Wojcicki's sibling, entered into a research services agreement (TWF Agreement) with the company. Revenue from the TWF Agreement was $0.2 million for the three months ended June 30, 2025.
• The asset sale on July 14, 2025, was to 23andMe Research Institute, an affiliate of Anne Wojcicki, for $305.0 million.

Stakeholder Impact

• **Shareholders:** Significant negative impact due to Chapter 11 bankruptcy, delisting, and the planned wind-down, which implies minimal or no recovery for equity holders.
• **Employees:** Workforce reductions have occurred, and the company's wind-down will lead to further job losses, except for those potentially transitioning to the acquiring entity for the telehealth business.
• **Customers (PGS/Research Services):** The core genetic testing and research services business has been sold to a new entity (23andMe Research Institute), which has committed to maintaining existing privacy policies and customer data deletion rights.
• **Customers (Telehealth):** The Lemonaid Health telehealth business is planned for sale, indicating a potential change in ownership and service provision, though the company aims for continuity.
• **Creditors:** Liabilities are subject to compromise under Chapter 11, meaning the ultimate settlement amounts are uncertain and may be less than full value.
• **Suppliers/Vendors:** The company's wind-down will terminate existing relationships, though some liabilities are subject to compromise in bankruptcy.

Next Steps

• Sell Lemonaid Health, Inc. (telehealth business).
• Wind down the remainder of the company's operations.
• Distribute all remaining assets.
• Cease corporate existence.

Key Dates

Recommendation

The company is in Chapter 11 bankruptcy, has sold its primary assets, and explicitly states its plan to sell its remaining business and then cease to exist. This indicates a complete and irreversible failure of the business, making the stock essentially worthless for current equity holders. While there was a cash infusion from the asset sale, this cash will be used to satisfy creditors, and it is highly unlikely that any value will remain for common shareholders. The delisting from Nasdaq further reduces liquidity and visibility. A seasoned investor would recognize this as a terminal event for the equity.

Keywords

Bankruptcy, Chapter 11, Asset Sale, Wind-down, Delisting, Genetic Testing, Telehealth, Financial Results, SEC Filing, Liquidation, 23andMe, Lemonaid Health, Cybersecurity Incident